ArticleFrontiers in endocrinology2026
Evaluation of ten composite inflammatory indicators for sarcopenia in type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The value of composite inflammatory indicators in identifying sarcopenia in patients with type 2 diabetes mellitus (T2DM) remains unclear. This study investigated associations between ten composite inflammatory indicators and sarcopenia, aiming to identify optimal indicators for sarcopenia detection in T2DM. Methods: The ten indicators were: systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), pan-immune inflammation value (PIV), platelet-to-lymphocyte ratio (PLR), advanced lung cancer inflammation index (ALI), neutrophil-to-albumin percentage ratio (NPAR), platelet-to-neutrophil ratio (PNR), neutrophil-lymphocyte-platelet ratio (NLPR), and hemoglobin-to-red cell distribution width ratio (HRR). Associations with sarcopenia and severe sarcopenia were assessed using restricted cubic splines (RCS) and multivariable logistic regression. Receiver operating characteristic (ROC) curves evaluated their identification ability. Results: Sarcopenia prevalence was 34.1% ( Conclusion: Elevated SII, SIRI, PIV, NPAR, NLPR, and NLR were positively associated with sarcopenia in T2DM, while ALI was inversely associated. Among all composite inflammatory indicators, ALI demonstrated the best ability to identify sarcopenia and severe sarcopenia in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.